New York has filed a lawsuit against pharmaceutical giant Actavis over allegations of an anticompetitive moves to block generic competition that forced consumers to pay higher prices for an Alzheimer’s drug, according to reports.
NY Attorney General Eric Schneiderman filed a complaint against the Irish company on Monday that accuses the company of swapping out one version of its Namenda drug for another that had a longer period of time until its patent expired.
That plan, AG Schneiderman said, was aimed at blocking its generic rival from entering the market and violates both state and federal antitrust law.
”We’re sending a clear message to all pharmaceutical companies: Prioritizing profits over patients’ rights will not be tolerated,” the official said in a statement.
According to complaints, Actavis is discontinuing its Namenda drug to release a slow-release version of the same medication; Namenda’s patent is set to expire in October of next year.
The tactic is sometimes known as a “forced switch” that forces patients to switch medication, which delays entry of generic competition into the market.
Actavis did not immediately respond to requests for comment, reports said.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI